{"ticker": {"uuid": "dfff0e77-da15-466d-bb3e-bf68c97caaa6", "symbol": "GRCE", "name": "Grace Therapeutics, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Grace Therapeutics (GRCE) Advances FDA Resubmission Efforts for GTx-104", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOOVhrQ2lOZG5nQlJZWGxDeEdaRTR1akFacHNyTzZJci1QS0V4LWlrLVhxa0lTazM3aWFjaENKel9GaVo0eUl2bEZVTTRUWG9BOG5Gd1Nha0FsblFSMjVNaUhwVzNVT0FFY21pMi1jZDczVXBPajU3azd3OEplSGRCUzgxUEsydGtTQjMyaDExT0h0LUdyWTFIYWtDb1ItU2ZLUlZueTA5M1h4V0JyZXN1bWJma3cwNWdOUWg0?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T22:13:09+00:00", "published_display": "18 Jun 2026 22:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics, Inc (GRCE) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFAwamdYcVVzS0daTUh5S05MUElncTdpelJ6NklZOFZJTWpKOVh1ZDJEdDh3MFF3VV9keE9UZHZzQnVhbk1MODBYMFk4LWgwNUpzZEROdm9jNGxFdUg3Sl9IVnVWNXczQk8xWm01d2gyR2VQcnNMWFNESQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T16:03:39+00:00", "published_display": "18 Jun 2026 16:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (NASDAQ: GRCE) updates GTx-104 data, FDA CRL response and cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNeGZYOVdnUWw4djViUDh3NVA1dXFZd0hTMHJVYUU5VU02NkVrZ0JSMFdHRzhKTnJZcHNzQXVWR2xwMTl3bkc3dXhjNWJVdHlFTmZ5TVNIYUZlNGZJQVIwdEhBeGItcWRLV3VQck1LQ3pDTVpWWTdkWVFhTC1fbGs0d0huWm14MVY3ZGtiSEUyZldDbUpUM2N0WTJET1djczZoZ3ZPZ1VDeGFqekVGbERTVg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T12:15:34+00:00", "published_display": "18 Jun 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (NASDAQ: GRCE) narrows 2026 loss and details FDA path for GTx-104", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQYXlxSkJyclE2TXNLbmdOT0RUdGVuNU9EN0JpNjRwbFM2QngzdV9vdVlqczg2bjU1NzNLX0g0aC1fQWpyTkt2MDkzV056amhHaHZWcnZzYWdVdEgwa3R0LVNoQWs5SXY2VXBOdmU0SEFuUHgzV1NHMnZZbU5tckZtTFFpY2JxODhjLV9JWlhlb3BHaEkxYnhKM2hDTzhjV0psTzhiT05HVEVabFBQbkh0eA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T12:01:22+00:00", "published_display": "18 Jun 2026 12:01", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAJBVV95cUxNMkptMmxnUVNFUmNRanl4UFV4eFVOUE13d2IyNUZtRTRSX0dwLWF6bFNJM0E5SnFlRDRGOG5PRVlaWTl3VjNxck1yVzBQNERVTU15cTJIcm9SVnhqTUt4bHI3ZGVoTENxMTV5cy1TT1Z4STJoM3RpdE5iRU5PZThGUU44anJMcXpCUV9MQ09ZSTlkQW1vSTZVZTFNSDd2QjZjY0xBd3ZhSzJlV292cXJuaU5pMEpOdnRRZWhyMk5ESENfbzRtSDliMUVZWGtqVWx0ZWFOUWVDTGlKUUJnTDR0Rk1wdVExYUE5ck5qdE55cUVGYVU3S0l0VXZ2YkdLN195LXVHWVlJUDg?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-18T12:00:00+00:00", "published_display": "18 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics sets FDA meeting after GTx-104 CRL", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPS3o0ZDY0VTJ1QkJrZ0RHenE4R1ZoRWtmTnltTloxbHJ2Ykt3VTBBbGVoaTZBR0pJVzRZN2szM1B5Y3hKSnhseldoclJGLVNxZFUxeXRMbmFMYUl1M0dKOEJqZkxDRTV2dDVpTGFhQnhUR1ptd3VyR2tSOHl1QjEwT1hOY0hkV2RFWGVobkQ2Qm9LYk96TjgyQ0dveVNtQUN3MUQ5SURZTmVIcldmNTJnd3k3WG8xajg5Yy11ay01dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T12:00:00+00:00", "published_display": "18 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOYXVrUHVFQmhuQ0I0NzR6blE0UG5XUUpVMVppVllBTVF6Skh4ZkxKbHUxRTl0a216ZU52SUhrYlhiNE1EMGJSYUREcTQ0TGpESjJVN2o2SnBIcTQwZHBENUI5a3Vsem5KZ0VTMkFXMEpxUjB1UTI0WVFiSEVtVGNXZkFzZTZMYXY5YnA1Z0xwRnZGd0Z0OGxOSGMyZXFRTGxpV2ttN0k4ZndlMlRaQ2NFSkFzajhXUQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-18T12:00:00+00:00", "published_display": "18 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace: Fiscal Q4 Earnings Snapshot", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQbE9PUUlRNTRZZHBMWjM0SnZqNmdMTk5SRTNNQmgyczZ3eWZrdGh4bFNiQzRCNnVwemtxWV92bkY4TzVGXzJwTU9pZklPbUxtOG1jd3d5ck9sWTBkRVlBbVI4TzdCSjRpdkgzNXotRXNFRno4Ymk1NUNrdkVncDQ4WTVYc0hER1pmQlB6UmJnbw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-18T11:47:06+00:00", "published_display": "18 Jun 2026 11:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (Nasdaq: GRCE) faces GTx-104 FDA CRL and writes down two pipeline drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNb2lSLWhDWHIyWVFTN2FWYXVTN0VhM18tajAxNWV5blhXdzVPN1d4S1pmMHBWVGhlbF90TWJUZVdPcFpZbE4xLVBCS2Nsc2NMSXVHNE5fV2xTMmc3RzFla0VnYkxsQTFidzNkZGJYZVhqb2xnNk00dUxyQWZFNExaWHBBN0Y5b01pV2lGenZSUnF5aDZQS1hielBtSHZuM3JmMVVkUlk2YVR5cnBuU3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T11:31:07+00:00", "published_display": "18 Jun 2026 11:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (NASDAQ: GRCE) VP departs, enters 12\u2011month consulting agreement", "summary": "Grace Therapeutics (NASDAQ: GRCE) announced that Carrie D\u2019Andrea will cease her role as VP of Clinical Operations effective June 5, 2026, and will receive severance benefits. Concurrently, she has entered into a 12-month consulting agreement for $250 per hour, during which her st", "url": "https://www.stocktitan.net/sec-filings/GRCE/8-k-grace-therapeutics-inc-reports-material-event-7020e8b8b8fc.html", "source_name": "Stock Titan", "published_at": "2026-06-06T08:09:31", "published_display": "06 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics: A Manufacturing Setback Priced As A Death Sentence (NASDAQ:GRCE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQSmhicWNPa2l2OTRkSTVNdmlaUWtKSmNvcHl1bjlhYjJGZ2dVaWRpNWtmbFhwLVI3WTZ1enNEN1NNZFN6NnpPb2g1VUprTmVmNHNKUkpib3c4dnFOMzZ3ZGtyNFFGZ0kwOFBHYTgyMjRlS0JoUVlKX2NpZnk2SlRiUEpraVBVT3NwOE5IWWo5UEpPSWtGZVdwTWthd0ViZ2NLUUR1S0g4Y0FKbzlFVGU4RnppT2U?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADAR1 reports 1.72M shares in Grace Therapeutics (GRCE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPR2ZKYjdTbmVKOVd5V21nSXBHZkh4SUxvS3hkSmpsbTFhdC0yUUg1aEp2WVRIcnJsek9mOXhlcDNyamg2UjBlV0pMT0tvc3hidlVYYldUaGZ1bTg1Ql8tNTlwOFdNamN1SmFaU2ROTi1XTElpOWp5NlRRcjlkTnN1NWpDSjR2MXYzMjdweVhMaWhhRHY0NFlYaW1hRjhzbHRHVUlpeHVzVnFWeFBiRXozbUdBVHE1SUZJaDZZZ3Y1dS1zbEJYdHUtY2gwWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Grace Therapeutics (GRCE) outlines GTx-104 CRL, Phase 3 data and cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNbW9mQlA2OWJmM0dpTzJjeE1ia1ZOQWgxV0x5QTVlcUdCaEFIWHNGb1VPTzB3TUl0M0s0cEQwOWt6c0l4TTFOWnA2UUNlN1ZJTFNiVEw5M3F1T2tkVEtaaDFVZ1cwQXlQVnBMWVJIZlRaOFBockxSaWpneFg0clZ4dVQtaE9jcXpacTJ6ZlUzVDkzX3dqMGx3T29CYTZMeEZUT3I1U2VxUnVoaXBtRUJRRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "814,000-share position reported by AIGH, Orin Hirschman in Grace Therapeutics (GRCE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQRGJ1TFN6bkVpcjJrbnpucWNFYURneWRkYXczOXJaRmtabFZCQVRjRXpaSXUxblZKbk03aFRwdUExOVhickNmbUlrVnNSMnZqTy1jNFYtX2g3cWpVV0d1aENPR2U2SXNmLUNHdzQzcFJlQjZvQWF3YlBkZ2Z2ckl6QWtqZGxDTUxGNU1rRU1RM2NuUE8wZmI1MENKWXFSbWlaRmlZN2RVOXhSSDRnX3ZaYTQwa2ZValBjY2F3UVNMcEZoeWhzSFFiZFN4cw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/grace-therapeutics-provides-regulatory-drug-171300897.html", "source_name": "GlobeNewswire", "published_at": "2026-04-23T17:13:00+00:00", "published_display": "23 Apr 2026 17:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA sends Grace drug application back over manufacturing issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQLTk0TlRhWlB2b0xmMjU2dnZDNVBoZm51c1ZvSzNPcXNKNkJ0UHBwRzZ2dHFOMkh5VU44cm00ZkNvZl92N3NCZkQzX3NQVk1zZXBUVU9rZnZMUmh1OEFPN2RadHhMLUVQSi1vd05CNGxIbGdJQkFEUTZDVGZlakhJdW1mT1NtOTRZWklIaGVKOFdtNXFMUkpFdFg0Mzk3WkdLYlhlMUNBRzIwdE5sUlRaTGJn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA flags CMC, non-clinical issues in Grace (NASDAQ: GRCE) GTx-104 NDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPZ0owdXpOU241MWFGMERLQndDR0I1UXhRMTdMY0VxTHJVSjFuSG9CaDRtSkdLRWhMeTNuaWJXYU52b21fdEhscXM5M2lhWjk2eWlkeEVsYS0xQ0JHUVBOcnFSNkpTa2thTkd0aVYtVHFwQUdLaUIwajdiYmR4cDNpSnpaY0haaTQ0V2JkNG1Dckl5c1M5dG93VmhYSmVpejBBQUlYaWZsdGJ1aFJYTmZLZQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA declines Grace's stroke drug over manufacturing and packaging issues, shares slump", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNMk9FNHZxSU9wVnNaQmFHUldUSzlRRTQxUU1WRUdlUW9zTWZoZjZ0bXF1YUc1MnNiNy1VMmhMSjBYekJ4WXRYOXI1bU1HekNSWjhaWGRFdWZydVRUVENLb1l1VWNHSnFUeG5HZXdRSmpFeENVeHFXNUNIUjE0TXF0ZFdCTURZX3ZVMjlZdkx0REtLOWRSTXByRnF2TnBscW9EcjA0dUplSWw5dllWZ21SUXV3?oc=5", "source_name": "Reuters", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRCE Stock Price and Chart \u2014 NASDAQ:GRCE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1ZRFNicEhBd0hIWktmUkhmazN5UExLc2lLM1Bla2wybk1tVW5pQWd2VFZEbDJOZTZlcGhLdllYQ1dyZ19SaEY1V0c0bHBPV05MRXpzbWNCeDFCVE1B?oc=5", "source_name": "TradingView", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/grace-therapeutics-announces-abstract-highlighting-120000616.html", "source_name": "GlobeNewswire", "published_at": "2026-04-14T12:00:00+00:00", "published_display": "14 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace lands AAN 2026 poster slot for Phase 3 GTx-104 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPek00LVNlaldmODlVTUZTNkF0enJSVEVHaGZreHhxd2k5SHRkX1lydEFBQ3dfam9uLWhRcVB2N25iblVGTWFCMmZrbHFCSkVVYXV3dngzM0R1V0hHdXRrandpVFB0YTVyeG1PTFYwNUM3QzltVHhERjBaVTlKTXpwZFIwMnVMXzBKOHlPSmVGazVBcGIyNDFDS2dOby0zUi1TQ1FiQ0xUZVF1Zzk1bnJadFA0MFhTUFN6ZmFDSDF6M1k?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics, Inc.'s (NASDAQ:GRCE) Path To Profitability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNdlhsWXI0UHlvdl9PUTRvRjlTNDJyS3o5WTlyWXRPWGZPRFFuc0lwbWhXak5laVZGaWg4ZzhZTkN4WW1Kc0podWx4eV9OaDBHdjdNMmtUT2kwU3ZmMFJGQk5NUk5CM24ybTh5eUZTQTlNRWtQQTNVMUN2RXMxVjFZdm9PN1FCR1RRTy1EMTcxNzFyamhZUDNJ?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "April 23 FDA target date set for Grace\u2019s GTx-104 aSAH drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNRll2alRpLTREYTJkSnBxTjdYZkViVmVRUmpLQ3lwMmw4SUtoenZtblhJS09heVpjN2xVemxSUlhUZ0JmTmhlelVJdTRoRDhhTkJsRVJfYWstekp5WUswdExnVTV3ZmtFOEFEdV9FbkxMcVFRMmNMLVEteGJSeHhrcmR6V3duMlEyZm84bzJLRU5pbXpRa2p5LUtaY3dYZDYtX2Rpd3p6dHNleVNqQmxjdEk1dkVybmVnWEpiRw?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Grace Therapeutics (NASDAQ: GRCE) NDA accepted; PDUFA April 23, 2026, new dosing patent", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOX1VDdnFoZEt0Vnp5WTRvemJvaTE2eFFmTkZlaW5nRUhVTzdoZk1FQnZ5b1BIZFhvWGlBZEEySkxCQ0QzdnpvS1dqUVRCVG0zVXFaem91Wk4tREpBQnRrSXRLaGlYZ2FPRUNzU2xaaE1nWk9CUTRYOHgtbTVtSHVFaWpqLXNDbS1aTXhjRm5ySW1OVjlpOXJzRmJLbllWWnVvV253TVFqQ1FJS2t6WE03WDZ3LS1jZUxvY3dQdlZB?oc=5", "source_name": "Stock Titan", "published_at": "2025-11-13T13:02:52+00:00", "published_display": "13 Nov 2025 13:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (NasdaqCM:GRCE) Stock Price", "summary": "This article provides a company overview and financial data for Grace Therapeutics (NasdaqCM:GRCE). It highlights the company's market capitalization, recent stock performance, and key financial details such as zero revenue and a reported earnings loss of $6.0 million. The compan", "url": "https://simplywall.st/stock/nasdaqcm/grce", "source_name": "Simply Wall Street", "published_at": "2025-07-28T00:39:41", "published_display": "28 Jul 2025 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics Secures $30M Funding After Phase 3 Success, FDA Filing Set for Novel Hemorrhage Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPQWtiZzJlaEhldFVSRzNiNnFmYUVfUWUwYmd2RTdzUlYzZFNkcG1hck9WZnZFTUM4blEtUTg2akU4MmlVbS1pc29IRElpZ1dwWmdROW5wMkVFR0VrMFEyaWxuaEtDc1l0MEZ0T3MtWElxYlJJNUhfRFU3YU5oUlFVd1VsTk9wQUVxQjNtSFFHWW9hZzY0UTdrU2JzZjlTaHVGTmEya1R3U3dkenhkOXFvTEJlMW5yNHNxSjBjN1l3?oc=5", "source_name": "Stock Titan", "published_at": "2025-06-23T07:00:00+00:00", "published_display": "23 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRCE Stock Price, News & Analysis | Grace Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5YclBiSzJxRWdZRGlUMEpHZWZHSUxSYUp1aFNxbHc2QUNwbUxod3EzV21jX3VCbVpnR2JzWlFuQjUyX3VqUmdDNGNneExDaF94N2RN?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T13:58:46+00:00", "published_display": "25 Apr 2025 13:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics And 2 Other US Penny Stocks Worth Watching", "summary": "This article highlights three US penny stocks\u2014Grace Therapeutics, X4 Pharmaceuticals, and Koil Energy Solutions\u2014that investors might find interesting due to their potential for significant returns, despite the inherent risks. It details their financial health, operational overvie", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xfor/x4-pharmaceuticals/news/grace-therapeutics-and-2-other-us-penny-stocks-worth-watchin", "source_name": "Simply Wall Street", "published_at": "2024-12-20T00:00:00", "published_display": "20 Dec 2024 00:00", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (GRCE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9XR2paX0JnWk9rNThqNzhuaEk1M2VGTC1fejAwdTdoajJ3V2lMMGU5XzFERUh6ZDBQWUVFd1lsX0I5MXhKQ0dIaWZmYTJEV2hRMGswQ25jU05MUQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-11-28T06:58:23+00:00", "published_display": "28 Nov 2024 06:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.", "summary": "Acasti Pharma Inc. announced its corporate name change to Grace Therapeutics, Inc., effective October 28, 2024, with its trading symbol on Nasdaq changing to \"GRCE.\" This rebranding reflects the company's focus on scientific innovation dating back to the pre-merger Grace Therapeu", "url": "https://finance.yahoo.com/news/acasti-announces-corporate-name-change-120000420.html", "source_name": "Market source", "published_at": "2024-10-25T12:00:00", "published_display": "25 Oct 2024 12:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acasti Pharma transitions to Grace Therapeutics, trading as GRCE By Investing.com", "summary": "Acasti Pharma is rebranding to Grace Therapeutics, Inc. and will trade on Nasdaq under the ticker GRCE starting October 28, 2024. The change reflects a return to the company's original identity and its focus on scientific innovation, particularly for its lead drug candidate GTx-1", "url": "https://ca.investing.com/news/company-news/acasti-pharma-transitions-to-grace-therapeutics-trading-as-grce-93CH-3664574", "source_name": "Investing.com Canada", "published_at": "2024-10-25T09:02:00", "published_display": "25 Oct 2024 09:02", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acasti Pharma transitions to Grace Therapeutics, trading as GRCE", "summary": "Acasti Pharma is rebranding to Grace Therapeutics, Inc. and will trade under the new ticker symbol GRCE on Nasdaq starting October 28, 2024. This change marks a return to the company's original identity from before its 2021 merger with Acasti, signaling a renewed focus on its lea", "url": "https://www.investing.com/news/company-news/acasti-pharma-transitions-to-grace-therapeutics-trading-as-grce-93CH-3683503", "source_name": "Investing.com", "published_at": "2024-10-25T09:01:00", "published_display": "25 Oct 2024 09:01", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Grace Therapeutics (GRCE) Advances FDA Resubmission Efforts for GTx-104", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOOVhrQ2lOZG5nQlJZWGxDeEdaRTR1akFacHNyTzZJci1QS0V4LWlrLVhxa0lTazM3aWFjaENKel9GaVo0eUl2bEZVTTRUWG9BOG5Gd1Nha0FsblFSMjVNaUhwVzNVT0FFY21pMi1jZDczVXBPajU3azd3OEplSGRCUzgxUEsydGtTQjMyaDExT0h0LUdyWTFIYWtDb1ItU2ZLUlZueTA5M1h4V0JyZXN1bWJma3cwNWdOUWg0?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T22:13:09+00:00", "published_display": "18 Jun 2026 22:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics, Inc (GRCE) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFAwamdYcVVzS0daTUh5S05MUElncTdpelJ6NklZOFZJTWpKOVh1ZDJEdDh3MFF3VV9keE9UZHZzQnVhbk1MODBYMFk4LWgwNUpzZEROdm9jNGxFdUg3Sl9IVnVWNXczQk8xWm01d2gyR2VQcnNMWFNESQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T16:03:39+00:00", "published_display": "18 Jun 2026 16:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (NASDAQ: GRCE) updates GTx-104 data, FDA CRL response and cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNeGZYOVdnUWw4djViUDh3NVA1dXFZd0hTMHJVYUU5VU02NkVrZ0JSMFdHRzhKTnJZcHNzQXVWR2xwMTl3bkc3dXhjNWJVdHlFTmZ5TVNIYUZlNGZJQVIwdEhBeGItcWRLV3VQck1LQ3pDTVpWWTdkWVFhTC1fbGs0d0huWm14MVY3ZGtiSEUyZldDbUpUM2N0WTJET1djczZoZ3ZPZ1VDeGFqekVGbERTVg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T12:15:34+00:00", "published_display": "18 Jun 2026 12:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (NASDAQ: GRCE) narrows 2026 loss and details FDA path for GTx-104", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxQYXlxSkJyclE2TXNLbmdOT0RUdGVuNU9EN0JpNjRwbFM2QngzdV9vdVlqczg2bjU1NzNLX0g0aC1fQWpyTkt2MDkzV056amhHaHZWcnZzYWdVdEgwa3R0LVNoQWs5SXY2VXBOdmU0SEFuUHgzV1NHMnZZbU5tckZtTFFpY2JxODhjLV9JWlhlb3BHaEkxYnhKM2hDTzhjV0psTzhiT05HVEVabFBQbkh0eA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T12:01:22+00:00", "published_display": "18 Jun 2026 12:01", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAJBVV95cUxNMkptMmxnUVNFUmNRanl4UFV4eFVOUE13d2IyNUZtRTRSX0dwLWF6bFNJM0E5SnFlRDRGOG5PRVlaWTl3VjNxck1yVzBQNERVTU15cTJIcm9SVnhqTUt4bHI3ZGVoTENxMTV5cy1TT1Z4STJoM3RpdE5iRU5PZThGUU44anJMcXpCUV9MQ09ZSTlkQW1vSTZVZTFNSDd2QjZjY0xBd3ZhSzJlV292cXJuaU5pMEpOdnRRZWhyMk5ESENfbzRtSDliMUVZWGtqVWx0ZWFOUWVDTGlKUUJnTDR0Rk1wdVExYUE5ck5qdE55cUVGYVU3S0l0VXZ2YkdLN195LXVHWVlJUDg?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-18T12:00:00+00:00", "published_display": "18 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics sets FDA meeting after GTx-104 CRL", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPS3o0ZDY0VTJ1QkJrZ0RHenE4R1ZoRWtmTnltTloxbHJ2Ykt3VTBBbGVoaTZBR0pJVzRZN2szM1B5Y3hKSnhseldoclJGLVNxZFUxeXRMbmFMYUl1M0dKOEJqZkxDRTV2dDVpTGFhQnhUR1ptd3VyR2tSOHl1QjEwT1hOY0hkV2RFWGVobkQ2Qm9LYk96TjgyQ0dveVNtQUN3MUQ5SURZTmVIcldmNTJnd3k3WG8xajg5Yy11ay01dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T12:00:00+00:00", "published_display": "18 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOYXVrUHVFQmhuQ0I0NzR6blE0UG5XUUpVMVppVllBTVF6Skh4ZkxKbHUxRTl0a216ZU52SUhrYlhiNE1EMGJSYUREcTQ0TGpESjJVN2o2SnBIcTQwZHBENUI5a3Vsem5KZ0VTMkFXMEpxUjB1UTI0WVFiSEVtVGNXZkFzZTZMYXY5YnA1Z0xwRnZGd0Z0OGxOSGMyZXFRTGxpV2ttN0k4ZndlMlRaQ2NFSkFzajhXUQ?oc=5", "source_name": "Moomoo", "published_at": "2026-06-18T12:00:00+00:00", "published_display": "18 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace: Fiscal Q4 Earnings Snapshot", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQbE9PUUlRNTRZZHBMWjM0SnZqNmdMTk5SRTNNQmgyczZ3eWZrdGh4bFNiQzRCNnVwemtxWV92bkY4TzVGXzJwTU9pZklPbUxtOG1jd3d5ck9sWTBkRVlBbVI4TzdCSjRpdkgzNXotRXNFRno4Ymk1NUNrdkVncDQ4WTVYc0hER1pmQlB6UmJnbw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-18T11:47:06+00:00", "published_display": "18 Jun 2026 11:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (Nasdaq: GRCE) faces GTx-104 FDA CRL and writes down two pipeline drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNb2lSLWhDWHIyWVFTN2FWYXVTN0VhM18tajAxNWV5blhXdzVPN1d4S1pmMHBWVGhlbF90TWJUZVdPcFpZbE4xLVBCS2Nsc2NMSXVHNE5fV2xTMmc3RzFla0VnYkxsQTFidzNkZGJYZVhqb2xnNk00dUxyQWZFNExaWHBBN0Y5b01pV2lGenZSUnF5aDZQS1hielBtSHZuM3JmMVVkUlk2YVR5cnBuU3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T11:31:07+00:00", "published_display": "18 Jun 2026 11:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (NASDAQ: GRCE) VP departs, enters 12\u2011month consulting agreement", "summary": "Grace Therapeutics (NASDAQ: GRCE) announced that Carrie D\u2019Andrea will cease her role as VP of Clinical Operations effective June 5, 2026, and will receive severance benefits. Concurrently, she has entered into a 12-month consulting agreement for $250 per hour, during which her st", "url": "https://www.stocktitan.net/sec-filings/GRCE/8-k-grace-therapeutics-inc-reports-material-event-7020e8b8b8fc.html", "source_name": "Stock Titan", "published_at": "2026-06-06T08:09:31", "published_display": "06 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics: A Manufacturing Setback Priced As A Death Sentence (NASDAQ:GRCE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQSmhicWNPa2l2OTRkSTVNdmlaUWtKSmNvcHl1bjlhYjJGZ2dVaWRpNWtmbFhwLVI3WTZ1enNEN1NNZFN6NnpPb2g1VUprTmVmNHNKUkpib3c4dnFOMzZ3ZGtyNFFGZ0kwOFBHYTgyMjRlS0JoUVlKX2NpZnk2SlRiUEpraVBVT3NwOE5IWWo5UEpPSWtGZVdwTWthd0ViZ2NLUUR1S0g4Y0FKbzlFVGU4RnppT2U?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADAR1 reports 1.72M shares in Grace Therapeutics (GRCE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPR2ZKYjdTbmVKOVd5V21nSXBHZkh4SUxvS3hkSmpsbTFhdC0yUUg1aEp2WVRIcnJsek9mOXhlcDNyamg2UjBlV0pMT0tvc3hidlVYYldUaGZ1bTg1Ql8tNTlwOFdNamN1SmFaU2ROTi1XTElpOWp5NlRRcjlkTnN1NWpDSjR2MXYzMjdweVhMaWhhRHY0NFlYaW1hRjhzbHRHVUlpeHVzVnFWeFBiRXozbUdBVHE1SUZJaDZZZ3Y1dS1zbEJYdHUtY2gwWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (GRCE) outlines GTx-104 CRL, Phase 3 data and cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNbW9mQlA2OWJmM0dpTzJjeE1ia1ZOQWgxV0x5QTVlcUdCaEFIWHNGb1VPTzB3TUl0M0s0cEQwOWt6c0l4TTFOWnA2UUNlN1ZJTFNiVEw5M3F1T2tkVEtaaDFVZ1cwQXlQVnBMWVJIZlRaOFBockxSaWpneFg0clZ4dVQtaE9jcXpacTJ6ZlUzVDkzX3dqMGx3T29CYTZMeEZUT3I1U2VxUnVoaXBtRUJRRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "814,000-share position reported by AIGH, Orin Hirschman in Grace Therapeutics (GRCE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQRGJ1TFN6bkVpcjJrbnpucWNFYURneWRkYXczOXJaRmtabFZCQVRjRXpaSXUxblZKbk03aFRwdUExOVhickNmbUlrVnNSMnZqTy1jNFYtX2g3cWpVV0d1aENPR2U2SXNmLUNHdzQzcFJlQjZvQWF3YlBkZ2Z2ckl6QWtqZGxDTUxGNU1rRU1RM2NuUE8wZmI1MENKWXFSbWlaRmlZN2RVOXhSSDRnX3ZaYTQwa2ZValBjY2F3UVNMcEZoeWhzSFFiZFN4cw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/grace-therapeutics-provides-regulatory-drug-171300897.html", "source_name": "GlobeNewswire", "published_at": "2026-04-23T17:13:00+00:00", "published_display": "23 Apr 2026 17:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA sends Grace drug application back over manufacturing issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQLTk0TlRhWlB2b0xmMjU2dnZDNVBoZm51c1ZvSzNPcXNKNkJ0UHBwRzZ2dHFOMkh5VU44cm00ZkNvZl92N3NCZkQzX3NQVk1zZXBUVU9rZnZMUmh1OEFPN2RadHhMLUVQSi1vd05CNGxIbGdJQkFEUTZDVGZlakhJdW1mT1NtOTRZWklIaGVKOFdtNXFMUkpFdFg0Mzk3WkdLYlhlMUNBRzIwdE5sUlRaTGJn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA flags CMC, non-clinical issues in Grace (NASDAQ: GRCE) GTx-104 NDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPZ0owdXpOU241MWFGMERLQndDR0I1UXhRMTdMY0VxTHJVSjFuSG9CaDRtSkdLRWhMeTNuaWJXYU52b21fdEhscXM5M2lhWjk2eWlkeEVsYS0xQ0JHUVBOcnFSNkpTa2thTkd0aVYtVHFwQUdLaUIwajdiYmR4cDNpSnpaY0haaTQ0V2JkNG1Dckl5c1M5dG93VmhYSmVpejBBQUlYaWZsdGJ1aFJYTmZLZQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA declines Grace's stroke drug over manufacturing and packaging issues, shares slump", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNMk9FNHZxSU9wVnNaQmFHUldUSzlRRTQxUU1WRUdlUW9zTWZoZjZ0bXF1YUc1MnNiNy1VMmhMSjBYekJ4WXRYOXI1bU1HekNSWjhaWGRFdWZydVRUVENLb1l1VWNHSnFUeG5HZXdRSmpFeENVeHFXNUNIUjE0TXF0ZFdCTURZX3ZVMjlZdkx0REtLOWRSTXByRnF2TnBscW9EcjA0dUplSWw5dllWZ21SUXV3?oc=5", "source_name": "Reuters", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRCE Stock Price and Chart \u2014 NASDAQ:GRCE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1ZRFNicEhBd0hIWktmUkhmazN5UExLc2lLM1Bla2wybk1tVW5pQWd2VFZEbDJOZTZlcGhLdllYQ1dyZ19SaEY1V0c0bHBPV05MRXpzbWNCeDFCVE1B?oc=5", "source_name": "TradingView", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/grace-therapeutics-announces-abstract-highlighting-120000616.html", "source_name": "GlobeNewswire", "published_at": "2026-04-14T12:00:00+00:00", "published_display": "14 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace lands AAN 2026 poster slot for Phase 3 GTx-104 trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPek00LVNlaldmODlVTUZTNkF0enJSVEVHaGZreHhxd2k5SHRkX1lydEFBQ3dfam9uLWhRcVB2N25iblVGTWFCMmZrbHFCSkVVYXV3dngzM0R1V0hHdXRrandpVFB0YTVyeG1PTFYwNUM3QzltVHhERjBaVTlKTXpwZFIwMnVMXzBKOHlPSmVGazVBcGIyNDFDS2dOby0zUi1TQ1FiQ0xUZVF1Zzk1bnJadFA0MFhTUFN6ZmFDSDF6M1k?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics, Inc.'s (NASDAQ:GRCE) Path To Profitability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNdlhsWXI0UHlvdl9PUTRvRjlTNDJyS3o5WTlyWXRPWGZPRFFuc0lwbWhXak5laVZGaWg4ZzhZTkN4WW1Kc0podWx4eV9OaDBHdjdNMmtUT2kwU3ZmMFJGQk5NUk5CM24ybTh5eUZTQTlNRWtQQTNVMUN2RXMxVjFZdm9PN1FCR1RRTy1EMTcxNzFyamhZUDNJ?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "April 23 FDA target date set for Grace\u2019s GTx-104 aSAH drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNRll2alRpLTREYTJkSnBxTjdYZkViVmVRUmpLQ3lwMmw4SUtoenZtblhJS09heVpjN2xVemxSUlhUZ0JmTmhlelVJdTRoRDhhTkJsRVJfYWstekp5WUswdExnVTV3ZmtFOEFEdV9FbkxMcVFRMmNMLVEteGJSeHhrcmR6V3duMlEyZm84bzJLRU5pbXpRa2p5LUtaY3dYZDYtX2Rpd3p6dHNleVNqQmxjdEk1dkVybmVnWEpiRw?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (NASDAQ: GRCE) NDA accepted; PDUFA April 23, 2026, new dosing patent", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOX1VDdnFoZEt0Vnp5WTRvemJvaTE2eFFmTkZlaW5nRUhVTzdoZk1FQnZ5b1BIZFhvWGlBZEEySkxCQ0QzdnpvS1dqUVRCVG0zVXFaem91Wk4tREpBQnRrSXRLaGlYZ2FPRUNzU2xaaE1nWk9CUTRYOHgtbTVtSHVFaWpqLXNDbS1aTXhjRm5ySW1OVjlpOXJzRmJLbllWWnVvV253TVFqQ1FJS2t6WE03WDZ3LS1jZUxvY3dQdlZB?oc=5", "source_name": "Stock Titan", "published_at": "2025-11-13T13:02:52+00:00", "published_display": "13 Nov 2025 13:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (NasdaqCM:GRCE) Stock Price", "summary": "This article provides a company overview and financial data for Grace Therapeutics (NasdaqCM:GRCE). It highlights the company's market capitalization, recent stock performance, and key financial details such as zero revenue and a reported earnings loss of $6.0 million. The compan", "url": "https://simplywall.st/stock/nasdaqcm/grce", "source_name": "Simply Wall Street", "published_at": "2025-07-28T00:39:41", "published_display": "28 Jul 2025 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics Secures $30M Funding After Phase 3 Success, FDA Filing Set for Novel Hemorrhage Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPQWtiZzJlaEhldFVSRzNiNnFmYUVfUWUwYmd2RTdzUlYzZFNkcG1hck9WZnZFTUM4blEtUTg2akU4MmlVbS1pc29IRElpZ1dwWmdROW5wMkVFR0VrMFEyaWxuaEtDc1l0MEZ0T3MtWElxYlJJNUhfRFU3YU5oUlFVd1VsTk9wQUVxQjNtSFFHWW9hZzY0UTdrU2JzZjlTaHVGTmEya1R3U3dkenhkOXFvTEJlMW5yNHNxSjBjN1l3?oc=5", "source_name": "Stock Titan", "published_at": "2025-06-23T07:00:00+00:00", "published_display": "23 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GRCE Stock Price, News & Analysis | Grace Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5YclBiSzJxRWdZRGlUMEpHZWZHSUxSYUp1aFNxbHc2QUNwbUxod3EzV21jX3VCbVpnR2JzWlFuQjUyX3VqUmdDNGNneExDaF94N2RN?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T13:58:46+00:00", "published_display": "25 Apr 2025 13:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics And 2 Other US Penny Stocks Worth Watching", "summary": "This article highlights three US penny stocks\u2014Grace Therapeutics, X4 Pharmaceuticals, and Koil Energy Solutions\u2014that investors might find interesting due to their potential for significant returns, despite the inherent risks. It details their financial health, operational overvie", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xfor/x4-pharmaceuticals/news/grace-therapeutics-and-2-other-us-penny-stocks-worth-watchin", "source_name": "Simply Wall Street", "published_at": "2024-12-20T00:00:00", "published_display": "20 Dec 2024 00:00", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Grace Therapeutics (GRCE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9XR2paX0JnWk9rNThqNzhuaEk1M2VGTC1fejAwdTdoajJ3V2lMMGU5XzFERUh6ZDBQWUVFd1lsX0I5MXhKQ0dIaWZmYTJEV2hRMGswQ25jU05MUQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-11-28T06:58:23+00:00", "published_display": "28 Nov 2024 06:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.", "summary": "Acasti Pharma Inc. announced its corporate name change to Grace Therapeutics, Inc., effective October 28, 2024, with its trading symbol on Nasdaq changing to \"GRCE.\" This rebranding reflects the company's focus on scientific innovation dating back to the pre-merger Grace Therapeu", "url": "https://finance.yahoo.com/news/acasti-announces-corporate-name-change-120000420.html", "source_name": "Market source", "published_at": "2024-10-25T12:00:00", "published_display": "25 Oct 2024 12:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acasti Pharma transitions to Grace Therapeutics, trading as GRCE By Investing.com", "summary": "Acasti Pharma is rebranding to Grace Therapeutics, Inc. and will trade on Nasdaq under the ticker GRCE starting October 28, 2024. The change reflects a return to the company's original identity and its focus on scientific innovation, particularly for its lead drug candidate GTx-1", "url": "https://ca.investing.com/news/company-news/acasti-pharma-transitions-to-grace-therapeutics-trading-as-grce-93CH-3664574", "source_name": "Investing.com Canada", "published_at": "2024-10-25T09:02:00", "published_display": "25 Oct 2024 09:02", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Acasti Pharma transitions to Grace Therapeutics, trading as GRCE", "summary": "Acasti Pharma is rebranding to Grace Therapeutics, Inc. and will trade under the new ticker symbol GRCE on Nasdaq starting October 28, 2024. This change marks a return to the company's original identity from before its 2021 merger with Acasti, signaling a renewed focus on its lea", "url": "https://www.investing.com/news/company-news/acasti-pharma-transitions-to-grace-therapeutics-trading-as-grce-93CH-3683503", "source_name": "Investing.com", "published_at": "2024-10-25T09:01:00", "published_display": "25 Oct 2024 09:01", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 40, "sentiment_summary": {"positive": 5, "negative": 3, "neutral": 32, "score": 51, "total": 40, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 12.25, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 5.64, "count": 12}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 2.38, "latest_week": "2026-06-19", "one_week_move": 8.2, "four_week_move": 8.2, "twelve_week_move": -49.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.0976, "market_dynamics_buy_signal": false, "relative_strength": -40.489372, "fair_value_gap": -25.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 54.8922, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.2% over one week, +8.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 15}, {"label": "Market source", "count": 7}, {"label": "simplywall.st", "count": 3}, {"label": "GlobeNewswire", "count": 2}, {"label": "Simply Wall Street", "count": 2}, {"label": "GuruFocus", "count": 1}, {"label": "TradingKey", "count": 1}, {"label": "The Globe and Mail", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 33}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 12}, {"label": "Balance sheet", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "33", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+8.2% over one week, +8.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Grace Therapeutics (GRCE) Advances FDA Resubmission Efforts for GTx-104"}], "updated_at": "2026-06-22T12:47:33.607447+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}